Bladder Cancer is designed for researchers and clinicians involved in urologic practice, including urologists, medical oncologists, pathologists and radiologists. It provides comprehensive guidance for treating and understanding bladder cancer and serves as an up-to-date reference reflecting evidence-based research.
The biological behavior of this disease entity shows a heterogeneous pattern with diverse morbidity and mortality depending on a variety of factors, such as tumor characteristics (tumor stage, grade, size, number, shape, and histologic subtypes) and applied treatment modalities (surgery or non-surgical management).
This book presents the substantial academic developments in the field of bladder cancer in one convenient reference.
1. Cover image - p. Cover 2. Title page - p. iii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. List of Contributors - p. xxi 6. About the Editor - p. xxv 7. Preface - p. xxvii 8. Section I: Epidemiology, Etiology, and Pathophysiology - p. xxvii 9. Chapter 1. Epidemiology - p. 3 10. Chapter 2. Etiology (Risk Factors for Bladder Cancer) - p. 21 11. Chapter 3. Pathophysiology of Bladder Cancer - p. 33 12. Section II: Diagnosis - p. 39 13. Chapter 4. Symptoms - p. 45 14. Chapter 5. Physical Examination - p. 57 15. Chapter 6. Urine Cytology and Urinary Biomarkers - p. 67 16. Chapter 7. Cystoscopy - p. 83 17. Chapter 8. Bladder Cancer: Imaging - p. 87 18. Chapter 9. Transurethral Resection of Bladder Tumors - p. 123 19. Chapter 10. Recent Technological Advances in Cystoscopy for the Detection of Bladder Cancer - p. 135 20. Section III: Pathology and Staging - p. 143 21. Chapter 11. Histological Classification of Bladder Tumors - p. 147 22. Chapter 12. Tumor, Nodes, Metastases (TNM) Classification System for Bladder Cancer - p. 181 23. Section IV: Treatment for Nonmuscle Invasive Bladder Cancer (NMIBC) - p. 184 24. Chapter 13. Risk Factors for Recurrence and Progression of Nonmuscle Invasive Bladder Cancer - p. 187 25. Chapter 14. Treatment for TaT1 Tumors - p. 201 26. Chapter 15. Treatment for Carcinoma In Situ - p. 213 27. Chapter 16. Treatment for T1G3 Tumor - p. 231 28. Chapter 17. Single, Immediate, Postoperative Intravesical Chemotherapy - p. 241 29. Chapter 18. Second Transurethral Resection of Bladder Cancer - p. 255 30. Chapter 19. Intravesical Chemotherapy - p. 263 31. Chapter 20. Immunotherapy: Bacille Calmette–Guérin - p. 277 32. Chapter 21. Treatment of Failure of Intravesical Therapy - p. 327 33. Section V: Treatment for Muscle-Invasive Bladder Cancer (MIBC) - p. 332 34. Chapter 22. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer - p. 337 35. Chapter 23. Radical Cystectomy (RC) with Urinary Diversion - p. 353 36. Chapter 24. Open Techniques and Extent (Including Pelvic Lymphadenectomy) - p. 369 37. Chapter 25. Morbidity, Mortality, and Survival for Radical Cystectomy - p. 439 38. Chapter 26. Adjuvant Chemotherapy - p. 451 39. Chapter 27. Bladder-Sparing Treatments - p. 467 40. Chapter 28. Quality of Life in Bladder Cancer Patients - p. 507 41. Section VI: Chemotherapy for Metastatic Bladder Cancer - p. 519 42. Section VI. Chemotherapy for Metastatic Bladder Cancer - p. 523 43. Section VII: Follow-Up (Surveillance) - p. 535 44. Chapter 29. Surveillance for Non-Muscle-Invasive Bladder Cancer - p. 541 45. Chapter 30. The Surveillance for Muscle-Invasive Bladder Cancer (MIBC) - p. 553 46. Chapter 31. Novel and Emerging Surveillance Markers for Bladder Cancer - p. 599 47. Section VIII: Future Perspective in Bladder Cancer - p. 609 48. Chapter 32. Microbiome - p. 615 49. Chapter 33. Genetic Testing, Genetic Variation, and Genetic Susceptibility - p. 629 50. Chapter 34. CRISPR-Genome Editing - p. 651 51. Chapter 35. Personalized Medicine - p. 659 52. Index - p. 675
Bladder Cancer is designed for researchers and clinicians involved in urologic practice, including urologists, medical oncologists, pathologists and radiologists. It provides comprehensive guidance for treating and understanding bladder cancer and serves as an up-to-date reference reflecting evidence-based research.
The biological behavior of this disease entity shows a heterogeneous pattern with diverse morbidity and mortality depending on a variety of factors, such as tumor characteristics (tumor stage, grade, size, number, shape, and histologic subtypes) and applied treatment modalities (surgery or non-surgical management).
This book presents the substantial academic developments in the field of bladder cancer in one convenient reference.
1. Cover image - p. Cover 2. Title page - p. iii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. List of Contributors - p. xxi 6. About the Editor - p. xxv 7. Preface - p. xxvii 8. Section I: Epidemiology, Etiology, and Pathophysiology - p. xxvii 9. Chapter 1. Epidemiology - p. 3 10. Chapter 2. Etiology (Risk Factors for Bladder Cancer) - p. 21 11. Chapter 3. Pathophysiology of Bladder Cancer - p. 33 12. Section II: Diagnosis - p. 39 13. Chapter 4. Symptoms - p. 45 14. Chapter 5. Physical Examination - p. 57 15. Chapter 6. Urine Cytology and Urinary Biomarkers - p. 67 16. Chapter 7. Cystoscopy - p. 83 17. Chapter 8. Bladder Cancer: Imaging - p. 87 18. Chapter 9. Transurethral Resection of Bladder Tumors - p. 123 19. Chapter 10. Recent Technological Advances in Cystoscopy for the Detection of Bladder Cancer - p. 135 20. Section III: Pathology and Staging - p. 143 21. Chapter 11. Histological Classification of Bladder Tumors - p. 147 22. Chapter 12. Tumor, Nodes, Metastases (TNM) Classification System for Bladder Cancer - p. 181 23. Section IV: Treatment for Nonmuscle Invasive Bladder Cancer (NMIBC) - p. 184 24. Chapter 13. Risk Factors for Recurrence and Progression of Nonmuscle Invasive Bladder Cancer - p. 187 25. Chapter 14. Treatment for TaT1 Tumors - p. 201 26. Chapter 15. Treatment for Carcinoma In Situ - p. 213 27. Chapter 16. Treatment for T1G3 Tumor - p. 231 28. Chapter 17. Single, Immediate, Postoperative Intravesical Chemotherapy - p. 241 29. Chapter 18. Second Transurethral Resection of Bladder Cancer - p. 255 30. Chapter 19. Intravesical Chemotherapy - p. 263 31. Chapter 20. Immunotherapy: Bacille Calmette–Guérin - p. 277 32. Chapter 21. Treatment of Failure of Intravesical Therapy - p. 327 33. Section V: Treatment for Muscle-Invasive Bladder Cancer (MIBC) - p. 332 34. Chapter 22. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer - p. 337 35. Chapter 23. Radical Cystectomy (RC) with Urinary Diversion - p. 353 36. Chapter 24. Open Techniques and Extent (Including Pelvic Lymphadenectomy) - p. 369 37. Chapter 25. Morbidity, Mortality, and Survival for Radical Cystectomy - p. 439 38. Chapter 26. Adjuvant Chemotherapy - p. 451 39. Chapter 27. Bladder-Sparing Treatments - p. 467 40. Chapter 28. Quality of Life in Bladder Cancer Patients - p. 507 41. Section VI: Chemotherapy for Metastatic Bladder Cancer - p. 519 42. Section VI. Chemotherapy for Metastatic Bladder Cancer - p. 523 43. Section VII: Follow-Up (Surveillance) - p. 535 44. Chapter 29. Surveillance for Non-Muscle-Invasive Bladder Cancer - p. 541 45. Chapter 30. The Surveillance for Muscle-Invasive Bladder Cancer (MIBC) - p. 553 46. Chapter 31. Novel and Emerging Surveillance Markers for Bladder Cancer - p. 599 47. Section VIII: Future Perspective in Bladder Cancer - p. 609 48. Chapter 32. Microbiome - p. 615 49. Chapter 33. Genetic Testing, Genetic Variation, and Genetic Susceptibility - p. 629 50. Chapter 34. CRISPR-Genome Editing - p. 651 51. Chapter 35. Personalized Medicine - p. 659 52. Index - p. 675
